November 14, 2010New England Journal of Medicine2,948 citationsOpen Access
Ver artículo completoEplerenone in Patients with Systolic Heart Failure and Mild Symptoms
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
Eplerenone, as compared with placebo, reduced both the risk of death and the risk of hospitalization among patients with systolic heart failure and mild symptoms. (Funded by Pfizer; ClinicalTrials.gov number, NCT00232180.).